Spectrum Pharmaceuticals, Inc

Quick facts

Marketed products

• VLI · Oncology
  VLI is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, disrupting cell division and causing cell death in rapidly dividing cancer cells.

Phase 3 pipeline

• SPI-2012 · Oncology
  SPI-2012 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells.

Phase 1 pipeline

• [14C]-Poziotinib
• Belinostat, Warfarin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Spectrum Pharmaceuticals, Inc portfolio CI brief
• Spectrum Pharmaceuticals, Inc pipeline updates RSS